Eye ( We appreciate the interest shown by Vahdani et al 1 in a surgical technique we recently described 2 and their comments. We are glad to hear that this technique has been practised by fellow colleagues with similar good results achieved. We would also like to take this opportunity to address certain differences in techniques between practices.
Both series achieved high anatomical and functional success with punch punctoplasty using Kelly Descemet's membrane punch-95% anatomical success and 90% functional success compared to 94% anatomical success and 92% functional success in our series. In terms of surgical technique, compared to our methods, Vahdani et al described a more limited posterior ampullectomy involving only the vertical component of the canaliculus, with two to three bites. Review of literature revealed no existing reference suggesting the exact amount of tissue to be removed in punch punctoplasty. In our practice, we chose to extend the ampullectomy to 2-3 mm beyond the vertical component of the canaliculus as we believe that scarring and contraction during the healing process will eventually cause the punctal opening to become smaller. With our current technique, the extent of tissue trauma is still much less compared to the conventional 3-snip procedure, taking a balance between adequate tissue removal to prevent re-approximation of the raw cut ends of the ampulla causing failure, while limiting the destruction of the capillary action of the canaliculus to the punched out segment only. In our series, we did not encounter any major complications, but we may consider to further reduce the amount of tissue removal similar to that described by Vahdani et al.
Postoperatively, patients were prescribed topical antibiotics solely in Vahdani et al series. In our clinic, steroid and antibiotic combination eye drops are widely used, and we did not encounter steroid-related complications, given the short duration of usage. We believe the addition of steroid drops during early post-operative phase can reduce inflammation, and may theoretically slow down the scarring process and re-stenosis of the punctum.
With the presence of further evidence to support the use of punctoplasty using Kelly Descemet's membrane punch as an effective and minimally invasive treatment for symptomatic punctal stenosis, we hope its use can become more widespread in the future.
Sir, Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema
To date, few studies have published data to assess the effects of switching anti-VEGF therapies in diabetic macular oedema (DMO). 1-3 The purpose of this study is to gain a better understanding of the clinical effects of switching treatment from ranibizumab to aflibercept, and to assess the number of aflibercept injections required to achieve complete resolution of macular oedema.
Switching to aflibercept was considered in cases of suboptimal response after treatment with a minimum of three ranibizumab injections at 4-week intervals on diagnosis of DMO. Suboptimal response was defined as decrease in central retinal thickness (CRT) by 25-75%, but with presence of persisting subretinal or intraretinal fluid. Treatment with ranibizumab was continued as needed until no improvement in CRT was noted. Eyes exhibiting increase in CRT after the first three monthly ranibizumab injections were switched to aflibercept, after the third ranibizumab injection. Responses to aflibercept were assessed at 4-week intervals until complete resolution of macular oedema was noted.
The study included a total of 49 eyes of 49 patients (15 women), with a mean age of 67.48 ± 11.4 years. The mean CRT at presentation of treatment naive patients was 537.08 ± 122.65 μm, with a mean best corrected visual acuity (BCVA) of logMAR 0.63 ± 0.29. A mean number of 6.3 ranibizumab intravitreal injections were administered in a mean period of 6 months without resolution of intraretinal and/or subretinal fluid. In these cases, treatment was switched to aflibercept injections on a per-needed basis. The duration of follow-up after initiation of aflibercept injection was 24 weeks. During this period, patients received an average of 2.58 (2-4) aflibercept injections until complete resolution of macular oedema, with complete absence of intra-or sub-retinal fluid on OCT.
At the time of switching anti-VEGF treatment, the mean CRT was 432.58 ± 163.72 μm. After 6 months with aflibercept, the mean CRT was noted to decrease to 275.83 ± 82.38 μm. As per the primary outcome of the study, a significant mean decline in retinal thickness of 156.75 μm (Po0.001) was noted. The changes in mean BCVA after switching showed a statistically significant improvement from logMAR 0.71 ± 0.3 to logMAR 0.58 ± 0.18 (P = 0.008). These findings are demonstrated in Figure 1 , which highlights the changes in CRT and BCVA, respectively at three different time points: at presentation, before switching to aflibercept (during treatment with ranibizumab), and at 6 months after treatment with aflibercept. A statistically significant correlation between BCVA and CRT at presentation (rp = 0.565) and before switching (rp = 0.565) was noted. However, there was no significant correlation between the BCVA and CRT after switching treatment (rp = − 0.138) (Figure 2 ). Furthermore, a significant correlation was detected Figure 1 Change in mean BCVA (a) and CRT (b) at three time points: at presentation, before switching, and at 24 weeks after switching treatment to aflibercept. Statistically significant difference in BCVA and CRT was observed between various time points: presentation, before switching, and after switching treatment (P = 0.008 and Po0.001, respectively).
